Home » Stocks » BCAB

BioAtla, Inc. (BCAB)

Stock Price: $45.38 USD -1.14 (-2.45%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 1.53B
Revenue (ttm) 7.77M
Net Income (ttm) -20.76M
Shares Out 32.09M
EPS (ttm) -0.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $45.38
Previous Close $46.52
Change ($) -1.14
Change (%) -2.45%
Day's Open 46.76
Day's Range 44.97 - 48.15
Day's Volume 120,714
52-Week Range 31.02 - 48.15

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 week ago

SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, to...

Benzinga - 3 weeks ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider bu...

Other stocks mentioned: FL, GME, NTAP, ARVN, COUP, EOSE, GWRE, JKHY, MBIO, ODT, UPST, VST
PRNewsWire - 1 month ago

SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based thera...

PRNewsWire - 1 month ago

SAN DIEGO, Dec. 15, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based thera...

TheStreet - 1 month ago

San Diego, California-based BioAtla was founded to develop conditionally active biologics that 'exploit characteristic pH differences between the tumor microenvironment and healthy tissue.'

NASDAQ - 2 months ago

BioAtla, a Phase 2 biotech developing antibody therapies for solid tumor cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

SEC - 2 months ago

BioAtla, Inc. has filed to go public with an IPO on the New York Stock Exchange (NYSE).

About BCAB

BioAtla, a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatoc... [Read more...]

Industry
Biotechnology
IPO Date
Dec 16, 2020
CEO
Jay M. Short
Employees
35
Stock Exchange
NASDAQ
Ticker Symbol
BCAB
Full Company Profile

Financial Performance

In 2019, BioAtla's revenue was $5.20 million, a decrease of -51.07% compared to the previous year's $10.63 million. Losses were -$29.79 million, 2.81% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for BioAtla stock is "Buy." The 12-month stock price forecast is 50.00, which is an increase of 10.18% from the latest price.

Price Target
$50.00
(10.18% upside)
Analyst Consensus: Buy